Login
$AKBA
$0.64 +$0.08 (13.57%) Close

$AKBA SEC Filings

Filed On Filing
23 Oct 2026 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On October 21, 2026, Akebia Therapeutics, Inc. (the “Company”) received a deficiency letter (the "Notice") from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the...

14 Oct 2026 8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

On October 7, 2026, Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign his employment with the Company for personal reasons. His...

10 Aug 2026 Form 4: Butler John P., Director

Received 350,000 shares by exercise or conversion ($221K)

05 Aug 2026 S-8
05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition
01 Jul 2026 Form 4: Ostrowski Erik, SVP, CFO, CBO & Treasurer

Sold 56,019 shares ($62.2K)

30 Jun 2026 8-K: Regulation FD Disclosure; Other Events
29 Jun 2026 144
22 Jun 2026 Form 4: Wolf Myles, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Smith Cynthia, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Frieson Ron, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Zumwalt Leanne M, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Adams Adrian, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 Form 4: Rogers Michael W, Director

Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy)

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders
12 May 2026 SCHEDULE 13G
07 May 2026 10-Q
07 May 2026 8-K: Results of Operations and Financial Condition
29 Apr 2026 ARS

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support